Identifying Genetic Variations Associated with Risk of Prostate Cancer

Share this content:
While data confirmation is needed, recent findings may prove beneficial in identifying patients at a high risk of developing prostate cancer.
While data confirmation is needed, recent findings may prove beneficial in identifying patients at a high risk of developing prostate cancer.

Data from a multinational study has identified 22 genetic variations that appear to be associated with an increased risk of developing prostate cancer. The findings, which were published in Cancer Discovery, are based on a large-scale analysis of genetic variants within putative miRNA binding sites in prostate cancer.1

The investigators report that genome-wide association studies have identified 100 risk variants for prostate cancer.  However, those 100 risk variants only explain approximately 33% of the familial risk of the disease.

The researchers hypothesized that a comprehensive analysis of genetic variations found within the three untranslated regions of genes predicted the effect of miRNA binding (miRSNP), further identifying additional prostate cancer risk variants.

The researchers investigated the association between 2,169 miRSNPs and prostate cancer risk in a large-scale analysis of 22,301 prostate cancer cases and 22,320 controls of European ancestry from 23 participating studies.

This analysis was part of the PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) consortium whose goal is to identify genetic risk factors associated with prostate cancer. The researchers found that 22 miRSNPs were associated with risk of prostate cancer.

Importantly, seven of the variants could differentiate between aggressive and nonaggressive disease.

RELATED: Adding Radiotherapy to ADT Only Slightly Impacts Quality of Life in Prostate Cancer

The researchers further confirmed the importance of two of these genetic variants by investigating how they influence protein expression in normal and cancerous prostate tissue.

They discovered that one of the variants plays an important role in mediating expression of the prostate serum marker prostate specific antigen (PSA), and the second variant controls expression of a gene involved in metabolism.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs